Policy & Regulation
Pharming launches Joenja in Japan for APDS patients aged four and above
...
PTC to acquire BLA-stage ST-920 Fabry disease programme
13 August 2026 - US biopharmaceutical company PTC Therapeutics Inc (NASDAQ:PTCT) announced on Wednesday that it was selected as the winning bidder to acquire ST-920, a BLA-stage, one-time administered...
ArkBio's IND application for AFC candidate AK0406 approved in China for influenza prophylaxis
13 August 2026 - Chinese biopharmaceutical company Shanghai Ark Biopharmaceutical Co Ltd (ArkBio) announced on Wednesday that the Investigational New Drug (IND) application for AK0406 injection, the c...
Definium Therapeutics reports positive Phase 3 results for DT120 in generalised anxiety disorder
12 August 2026 - Late-stage clinical biopharmaceutical company Definium Therapeutics Inc (Nasdaq:DFTX) on Wednesday reported positive topline results from its Phase 3 Voyage study evaluating DT120 (ly...
Astorg completes acquisition of Thermo Fisher Scientific's microbiology business
12 August 2026 - Private equity firm Astorg announced on Wednesday that it has completed its acquisition of the global microbiology business of life science and clinical research company Thermo Fisher...
Natera to support Phase 1 trial of Kupando's immunotherapy in advanced skin cancers
12 August 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) said on Wednesday that it will provide its Latitude tissue-free molecular residual disease (MRD) assay for a Phas...